Patents by Inventor Taihei Nishiyama

Taihei Nishiyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210371379
    Abstract: 4-({(4S)-1-(4-Carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)piperazin-1-yl]-L-prolyl}amino) benzoic acid di(4-toluenesulfonate) or dibenzenesulfonate or their crystal forms can be useful pharmaceutical ingredients because of their low hygroscopicity and excellent storage stability.
    Type: Application
    Filed: September 19, 2019
    Publication date: December 2, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Taihei NISHIYAMA, Takahiro NEKADO
  • Publication number: 20210147403
    Abstract: COMPOUNDS The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 20, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira IMAGAWA, Takashi KONDO, Taihei NISHIYAMA, Steve COURTNEY, Chris YARNOLD, Osamu ICHIHARA, Stuart FLANAGAN
  • Patent number: 10899729
    Abstract: A method for producing a compound, such as 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate, and a novel intermediate suitable for the method, whereby the compound can be stably supplied with a high total reaction yield, by changing the starting material and improving the metathesis reaction, asymmetric reduction reaction and the like.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 26, 2021
    Assignee: ONO PHARMACEUTICAL CO.. LTD.
    Inventors: Hideki Moriguchi, Yusuke Tanaka, Tatsunori Ino, Tohru Kambe, Taihei Nishiyama, Shinichiro Tsujiyama, Yohei Ueda
  • Publication number: 20210009586
    Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
    Type: Application
    Filed: September 22, 2020
    Publication date: January 14, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Motoyuki TANAKA, Takashi KONDO, Yasuo HIROOKA, Taihei NISHIYAMA, Atsushi HIRAMATSU, Tomoyuki KODA, Sho KOUYAMA
  • Patent number: 10882855
    Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: January 5, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira Imagawa, Takashi Kondo, Taihei Nishiyama, Steve Courtney, Chris Yarnold, Osamu Ichihara, Stuart Flanagan
  • Patent number: 10815233
    Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: October 27, 2020
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Motoyuki Tanaka, Takashi Kondo, Yasuo Hirooka, Taihei Nishiyama, Atsushi Hiramatsu, Tomoyuki Koda, Sho Kouyama
  • Publication number: 20200140435
    Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 7, 2020
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Motoyuki TANAKA, Takashi KONDO, Yasuo HIROOKA, Taihei NISHIYAMA, Atsushi HIRAMATSU, Tomoyuki KODA, Sho KOUYAMA
  • Patent number: 10550119
    Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: February 4, 2020
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Motoyuki Tanaka, Takashi Kondo, Yasuo Hirooka, Taihei Nishiyama, Atsushi Hiramatsu, Tomoyuki Koda, Sho Kouyama
  • Publication number: 20190352304
    Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
    Type: Application
    Filed: July 31, 2019
    Publication date: November 21, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Motoyuki TANAKA, Takashi KONDO, Yasuo HIROOKA, Taihei NISHIYAMA, Atsushi HIRAMATSU, Tomoyuki KODA, Sho KOUYAMA
  • Publication number: 20190315705
    Abstract: A method for producing a compound, such as 2-propanyl 4-{(3S,5aR,6R,7R,8aS)-6-[(1E,3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-buten-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoate, and a novel intermediate suitable for the method, whereby the compound can be stably supplied with a high total reaction yield, by changing the starting material and improving the metathesis reaction, asymmetric reduction reaction and the like.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 17, 2019
    Applicant: ONO PHARMACEUTICALS CO., LTD.
    Inventors: Hideki MORIGUCHI, Yusuke TANAKA, Tatsunori INO, Tohru KAMBE, Taihei NISHIYAMA, Shinichiro TSUJIYAMA, Yohei UEDA
  • Patent number: 10407426
    Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: September 10, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Motoyuki Tanaka, Takashi Kondo, Yasuo Hirooka, Taihei Nishiyama, Atsushi Hiramatsu, Tomoyuki Koda, Sho Kouyama
  • Publication number: 20190263795
    Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.
    Type: Application
    Filed: May 10, 2019
    Publication date: August 29, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira IMAGAWA, Takashi Kondo, Taihei Nishiyama, Steve Courtney, Chris Yarnold, Osamu Ichihara, Stuart Flanagan
  • Patent number: 10336741
    Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: July 2, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira Imagawa, Takashi Kondo, Taihei Nishiyama, Steve Courtney, Chris Yarnold, Osamu Ichihara, Stuart Flanagan
  • Publication number: 20180334458
    Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
    Type: Application
    Filed: July 31, 2018
    Publication date: November 22, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Motoyuki TANAKA, Takashi KONDO, Yasuo HIROOKA, Taihei NISHIYAMA, Atsushi HIRAMATSU, Tomoyuki KODA, Sho KOUYAMA
  • Patent number: 10065955
    Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: September 4, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Motoyuki Tanaka, Takashi Kondo, Yasuo Hirooka, Taihei Nishiyama, Atsushi Hiramatsu, Tomoyuki Koda, Sho Kouyama
  • Publication number: 20170349580
    Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
    Type: Application
    Filed: December 9, 2015
    Publication date: December 7, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Motoyuki TANAKA, Takashi KONDO, Yasuo HIROOKA, Taihei NISHIYAMA, Atsushi HIRAMATSU, Tomoyuki KODA, Sho KOUYAMA
  • Publication number: 20170137412
    Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.
    Type: Application
    Filed: January 23, 2017
    Publication date: May 18, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira IMAGAWA, Takashi KONDO, Taihei NISHIYAMA, Steve COURTNEY, Chris YARNOLD, Osamu ICHIHARA, Stuart FLANAGAN
  • Patent number: 9585881
    Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: March 7, 2017
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira Imagawa, Takashi Kondo, Taihei Nishiyama, Steve Courtney, Chris Yarnold, Osamu Ichihara, Stuart Flanagan
  • Publication number: 20160287582
    Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.
    Type: Application
    Filed: June 13, 2016
    Publication date: October 6, 2016
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira IMAGAWA, Takashi KONDO, Taihei NISHIYAMA, Steve COURTNEY, Chris YARNOLD, Osamu ICHIHARA, Stuart FLANAGAN
  • Patent number: 9394250
    Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: July 19, 2016
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira Imagawa, Takashi Kondo, Taihei Nishiyama, Steve Courtney, Chris Yarnold, Osamu Ichihara, Stuart Flanagan